The global human milk oligosaccharides (HMO) market was valued at USD 248.81 million in 2024. It is expected to expand from USD 275.34 million in 2025 to USD 879.86 million by 2032, registering a compound annual growth rate (CAGR) of 18.05% over the forecast period. In 2024, North America led the market with a share of 44.84%.

Human Milk Oligosaccharides are naturally occurring compounds found in mammalian breast milk, especially in humans, that contribute significantly to infant development and overall health. These bioactive molecules provide vital nutrition and are linked to several health benefits, including enhanced immunity, the promotion of a healthy gut microbiome, and protection against harmful microorganisms. As a result, leading infant nutrition brands such as Abbott Nutrition and Nestlé S.A. include HMOs in their formulations to enhance product performance and contribute to global market expansion.

Information Source: https://www.fortunebusinessinsights.com/human-milk-oligosaccharides-market-103822 

SEGMENTATION ANALYSIS

By Type: 2’FL Leads Due to Their Extensive Industrial Use

The market is segmented by type into 2’FL, 3’FL, 3’SL, 6’SL, and LNT, with 2’FL holding the largest share in 2024 due to its extensive use in infant formula and dietary supplements, supported by strong research and proven benefits. Other types like 3’FL, 3’SL, and 6’SL are less studied but are attracting growing interest from ongoing scientific research, which could drive their growth in the future.

By Structure: Neutral Fucosylated HMOs Dominate Due to Their Abundance in Human Milk

In terms of structure, the market is categorized into Neutral Fucosylated HMOs, Neutral HMOs, and Sialylated HMOs.
The Neutral Fucosylated segment accounts for the largest market share due to its high presence in human breast milk and broad functionality.

By Application: Infant Nutrition Segment Holds the Leading Market Share

Based on application, the market is segmented into infant nutrition, functional food and beverages, food supplements, and pharmaceuticals.
Infant nutrition remains the dominant application, driven by the widespread use of HMOs in baby formula to replicate the benefits of natural breast milk.

Human Milk Oligosaccharides Market Trends

Emerging Technologies and Alternative Sources to Enhance Product Development

The industry is witnessing rapid progress in identifying new sources and leveraging advanced manufacturing technologies to increase production efficiency and broaden application areas for HMOs.

Regional Outlook

The global market analysis includes North America, Europe, Asia Pacific, and other regions worldwide. In 2024, North America led the market with a value of USD 116.57 million, driven by key players and rising demand for advanced infant nutrition. Europe’s market is shaped by strict regulations classifying HMOs as novel foods to ensure safety and quality. Meanwhile, Asia Pacific is a high-growth region, with increasing demand for HMOs fueled by growing awareness and investment in infant and functional nutrition.

REPORT COVERAGE

This market report offers a detailed evaluation of the global human milk oligosaccharides industry, covering key trends, major companies, applications, and recent developments. It also presents statistical insights and tracks evolving market dynamics.

List of Key Companies Profiled:

• Koninklijke DSM N.V. (Netherlands)
• BASF SE (Germany)
• Chr. Hansen A/S (Denmark)
• International Flavors and Fragrances Inc. (U.S.)
• KYOWA HAKKO BIO CO., LTD. (Japan)
• Dextra Laboratories (U.K.)
• Inboise N.V. (U.S.)
• ELICITYL S.A (France)
• Abbott Laboratories (U.S.)
• FrieslandCampina (Netherlands)

Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-milk-oligosaccharides-market-103822 

KEY INDUSTRY DEVELOPMENTS

November 2023: Nestlé introduced a line of infant formula products enriched with HMOs in the Chinese market under its “Wyeth Illume” brand, marking a strategic step to meet growing regional demand for advanced infant nutrition solutions.